Sally Bennett
Senior Advisor and Board Member in the Bio-pharmaceutical Sector
Innate Pharma to participate in upcoming investor conferences
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming...
Innate Pharma reports First Quarter 2022 financial results and business update
First patient dosed in monalizumab Phase 3 lung cancer trial, PACIFIC-9 sponsored by AstraZeneca, which triggered a $50 million milestone payment extending Company cash runway into 2024 Monalizumab...
Number of shares and voting rights of Innate Pharma as of May 1, 2022
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...
Innate Pharma establishes an At-The-Market ("ATM") program on Nasdaq
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating...
Innate Pharma announces conference call and webcast for Q1 2022 Business Update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Tuesday, May 10, 2022 at 2 p.m. CEST / 8 a.m. EDT...
First patient dosed in monalizumab Phase 3 lung cancer clinical trial triggers $50M payment from AstraZeneca
First patient dosed in Phase 3 trial, PACIFIC-9, evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable, Stage III non-small cell lung cancer Milestone...
Innate Pharma to hold its Annual General Meeting of shareholders on May 20, 2022
The Annual General Meeting will be broadcasted live by the Company Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of...
Innate Pharma files its 2021 Universal Registration Document (Document d'enregistrement universel) and 2021 Annual Report on Form 20-F
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2021 Universal Registration Document (Document d’enregistrement universel) for the...
Innate Pharma reports Full Year 2021 financial results and business update
Monalizumab progressing to Phase 3 PACIFIC-9 lung cancer clinical trial in partnership with AstraZeneca First CD123 tri-specific ANKET TM starts Phase 1 study by Sanofi Lacutamab encouraging MF data...